The fertility printout that keeps coming back across the desk

She is thirty-one. Her name we will keep out of this. The printout is folded twice along its original crease and she slides it across the desk with a half-shrug, like she’s already a bit embarrassed. Around the headline, in pink marker, someone has circled the words “freeze your fertility, freeze the clock”. She wants to know what I think.

What I think, mostly, is that the article is a slightly nicer-looking version of one I read in 2013. Same field, same hopeful framing, same business model lurking behind the lifestyle copy. That year, a Melbourne woman became the first Australian to give birth after having ovarian tissue frozen, then put back. She’d had breast cancer eight years earlier. Tissue out before chemo, tissue back after remission, and at 43 she conceived without IVF. The MJA InSight write-up at the time was sober. The rest of the coverage was not. By the second weekend it had become “beat the menopause”, “switch off the ageing clock”, “frozen ovaries restore youth”. That was thirteen years ago. The framing has barely moved.

So I tell her the boring version, because that is what GPs do.

Yes, the technique works. Yes, it has worked better than the people who pioneered it dared say in print. By now there are well over two hundred live births worldwide from ovarian tissue freezing and reimplantation. The big series come out of Belgium, Denmark, the Netherlands. Australian centres have a respectable run going. The American Society for Reproductive Medicine took it off the experimental register back in 2019. So the 2013 story wasn’t wrong. It just got translated, somewhere between the press release and the Sunday lift-out, into a use case the science was never about.

The science was about cancer.

A woman in her twenties or thirties gets a diagnosis. Something that needs alkylating chemo, or pelvic radiation, or a marrow transplant. The plan is this. Take a wedge of ovarian cortex out laparoscopically, slice it into strips, drop the strips into liquid nitrogen. Treatment runs its course. If she does well and the disease stays away, the strips can be grafted back. Usually onto the remaining ovary, sometimes onto the broad ligament if there isn’t one left. The graft picks up its hormonal cues from the body. Follicles mature. Periods come back. Pregnancy is possible. For pre-pubertal girls facing the same chemo, this is the only option there is. You cannot retrieve eggs from a body that has never ovulated. That is where the real moral case has always sat, and it is rock solid, and it doesn’t need a lifestyle headline to defend it.

The bit that gets oversold is the rest.

The social version. Thirty-something woman, busy, no medical indication, considering a piece of her own cortex on ice as insurance against an unspecified future. I have seen this offered in glossy materials more than once. The studies do not support the language. Outcomes after autografting are best when the tissue was frozen before age thirty-five, which means anyone considering it as midlife insurance is already, on the data, running late. Retrieval is a real surgery, with the usual surgical risks. Grafts function for a median of around four to five years and then run out of follicles. Some grafts never take. The procedure is not bulk-billed. None of that fits in a magazine pull-quote.

When Sally Crossing of Cancer Voices Australia called the 2013 reporting over-hyped, she was talking about exactly this slippage. “It’s a terribly small group of patients involved and there needs to be more study,” she said. The patient group has grown since. The slippage has not closed. If anything the marketing has gotten more confident as the data has gotten better, because nuance is harder to sell than freeze-and-forget.

Look, I might be wrong about how hard to push back.

There’s a version of this conversation where I am the GP who lectures a thirty-one-year-old about realistic expectations and watches her walk out thinking I am out of touch. There’s another version where I keep my mouth shut and the magazine wins. Neither feels right. So we end up doing the slow thing. I ask her what she actually wants. Is it children. Is it the option of children. Is it a way to feel less frightened of getting older. The three answers point to three different conversations and only one of them ends with anything frozen.

The first time I had this exact conversation, I was a registrar. Melbourne, Friday afternoon, last patient of the week. She was a paediatric oncology nurse, of all people, someone who knew exactly what alkylating chemo did to ovarian reserve and was asking anyway. No diagnosis. A sister with breast cancer who had not banked tissue. The unbanked sister was the cautionary tale every family dinner kept circling back to. We talked for forty minutes. I don’t remember what she decided. I remember her bringing the same printout, more or less.

Reading the 2013 piece again for this column, the line that has aged best is from Gabor Kovacs himself. “We’ve now shown that this technique does work. We don’t know how well it works yet.” The hedge is doing all the heavy lifting in that sentence and almost everything around it has dated. We do, now, know how well it works for the cancer indication. For the social one, we still don’t, because the people willing to pay out of pocket to find out are few, the follow-up is short, and the studies that do exist are not powered for the question most patients are actually asking, which is, will this give me a baby in fifteen years.

So the printout goes back across the desk. I write down two phone numbers, neither of them the clinic in the article. One is the Royal Women’s in Melbourne. The other is her oncology-aware GP, in case the question is really about her sister. We agree she will come back in a month with whatever she has read. She does. She has read less by then. That, I admit, is the outcome I had hoped for. Most of the work in this part of medicine is reading less and asking better.

I think about that 2013 woman now and then. Her baby would be twelve. Finishing primary school somewhere in Australia, presumably oblivious to the small role he or she played in re-tilting a field that had been knocked sideways by a decade of bad reporting. I hope she’s well. I hope the field has earned its second decade. I am still, after all of this, less convinced about the headlines.